{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:14:57Z","timestamp":1782868497396,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17752-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:48:32Z","timestamp":1752140912000},"page":"7131-7140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion"],"prefix":"10.1245","volume":"32","author":[{"given":"Annie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellery H.","family":"Reason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany G.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wildman-Tobriner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. David","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K. M.","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Mantyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Zani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Uronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Lidsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"17752_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","volume":"18","author":"J Engstrand","year":"2018","unstructured":"Engstrand J, Nilsson H, Str\u00f6mberg C, Jonas E, Freedman J. Colorectal cancer liver metastases: a population-based study on incidence, management, and survival. BMC Cancer. 2018;18:78.","journal-title":"BMC Cancer"},{"key":"17752_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, et al. Treatment of metastatic colorectal cancer: ASCO guideline. JCO. 2023;41:678\u2013700.","journal-title":"JCO."},{"key":"17752_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905\u201314.","journal-title":"N Engl J Med"},{"key":"17752_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol"},{"key":"17752_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"17752_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23\u201330.","journal-title":"J Clin Oncol"},{"key":"17752_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jamcollsurg.2020.11.013","volume":"232","author":"R Anteby","year":"2021","unstructured":"Anteby R, et al. Getting chemotherapy directly to the liver: the historical evolution of hepatic artery chemotherapy. J Am Coll Surg. 2021;232:332\u20138.","journal-title":"J Am Coll Surg"},{"key":"17752_CR8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15187-y","author":"K Sugumar","year":"2024","unstructured":"Sugumar K, et al. Outcomes of hepatic artery-based therapies and systemic multiagent chemotherapy in unresectable colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-024-15187-y.","journal-title":"Ann Surg Oncol"},{"key":"17752_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"NE Kemeny","year":"2006","unstructured":"Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). JCO. 2006;24:1395\u2013403.","journal-title":"JCO"},{"key":"17752_CR10","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.hpb.2022.08.008","volume":"24","author":"M Cavnar","year":"2022","unstructured":"Cavnar M, et al. Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network. HPB Oxford. 2022;24:2104\u201311.","journal-title":"HPB Oxford."},{"key":"17752_CR11","doi-asserted-by":"crossref","unstructured":"Liu A, et al. Perioperative and oncologic outcomes of hepatic arterial infusion pump chemotherapy for patients with unresectable colorectal liver metastases at an expanding HAI program. Ann Surg Oncol. 2024. In press.","DOI":"10.1245\/s10434-024-16488-y"},{"key":"17752_CR12","unstructured":"ECOG-ACRIN Cancer Research Group. A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial. Retrieved 2024 at https:\/\/clinicaltrials.gov\/study\/NCT05863195."},{"key":"17752_CR13","doi-asserted-by":"publisher","first-page":"1418696","DOI":"10.3389\/fonc.2024.1418696","volume":"14","author":"JA Kalil","year":"2024","unstructured":"Kalil JA, et al. Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases. Front Oncol. 2024;14:1418696.","journal-title":"Front Oncol"},{"key":"17752_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2022.1026","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat. 2023;55:351.","journal-title":"Cancer Res Treat"},{"key":"17752_CR15","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1097\/JS9.0000000000001236","volume":"110","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study. Int J Surg. 2024;110:2776\u201387.","journal-title":"Int J Surg"},{"key":"17752_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/XCS.0000000000001028","volume":"238","author":"VV Bansal","year":"2024","unstructured":"Bansal VV, et al. Utility of circulating tumor DNA assessment in characterizing recurrence sites after optimal resection for metastatic colorectal cancer. J Am Coll Surg. 2024;238:1013\u201320.","journal-title":"J Am Coll Surg"},{"key":"17752_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.21037\/hbsn-23-310","volume":"12","author":"P Cnockaert","year":"2023","unstructured":"Cnockaert P, Muscari F, Maulat C. Utility of circulating tumor DNA in patients undergoing hepatectomy for colorectal liver metastases. Hepatobil Surg Nutr. 2023;12:736\u20139.","journal-title":"Hepatobil Surg Nutr"},{"key":"17752_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/cancers16050927","volume":"16","author":"H Hong","year":"2024","unstructured":"Hong H, et al. Circulating tumor DNA profiling in liver transplant for hepatocellular carcinoma, cholangiocarcinoma, and colorectal liver metastases: a programmatic proof of concept. Cancers Basel. 2024;16:927.","journal-title":"Cancers Basel"},{"key":"17752_CR19","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","volume":"23","author":"F Garlan","year":"2017","unstructured":"Garlan F, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017;23:5416\u201325.","journal-title":"Clin Cancer Res"},{"key":"17752_CR20","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1245\/s10434-020-08972-y","volume":"27","author":"JM Creasy","year":"2020","unstructured":"Creasy JM, et al. Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2020;27:5086\u201395.","journal-title":"Ann Surg Oncol"},{"key":"17752_CR21","unstructured":"Signorell A, et al. DescTools: tools for descriptive statistics. 2024."},{"key":"17752_CR22","unstructured":"Therneau TM, until (2009), T. L. (original S.->R port and R. maintainer, Elizabeth, A. & Cynthia, C. survival: Survival Analysis. 2024."},{"key":"17752_CR23","unstructured":"Sjoberg DD, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T. ggsurvfit: Flexible Time-to-Event Figures. 2024."},{"key":"17752_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13:570\u201380.","journal-title":"R J"},{"key":"17752_CR25","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.23.01540","volume":"42","author":"NN Rahbari","year":"2024","unstructured":"Rahbari NN, et al. Primary tumor resection before systemic therapy in patients with colon cancer and unresectable metastases: combined results of the SYNCHRONOUS and CCRe-IV trials. J Clin Oncol. 2024;42:1531\u201341.","journal-title":"J Clin Oncol"},{"key":"17752_CR26","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1245\/s10434-023-14207-7","volume":"30","author":"SJ Judge","year":"2023","unstructured":"Judge SJ, et al. Current practices in hepatic artery infusion (HAI) chemotherapy: an international survey of the HAI consortium research network. Ann Surg Oncol. 2023;30:7362.","journal-title":"Ann Surg Oncol"},{"key":"17752_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201:57\u201365.","journal-title":"J Am Coll Surg"},{"key":"17752_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/OP.23.00374","volume":"20","author":"D Rao","year":"2024","unstructured":"Rao D, Ellis CS, Kemeny N, Cercek A. Case-based clinical guidance on dosing and management of the hepatic artery infusion chemotherapy pump. JCO Oncol Pract. 2024;20:187\u201394.","journal-title":"JCO Oncol Pract"},{"key":"17752_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28:507\u201317.","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17752-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:06:17Z","timestamp":1758549977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17752"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17752-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John H. Strickler has a consultant or advisory role at Abbvie, Agenus, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche\/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics, and Triumvira Immunologics (stock options). He has received research funding or contracted research from Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche\/Genentech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}